Genenta Science SpA ADR (GNTA)
Genenta Science S.p.A. ADR (NASDAQ: GNTA) is a depositary receipt representing common stock of Genenta Science S.p.A., a clinical-stage biotechnology company based in Milan, Italy. The company is focused on developing hematopoietic stem cell gene therapies for solid tumors. Its lead candidate, Temferon, is in Phase 1/2a clinical testing for glioblastoma multiforme in patients with an unmethylated MGMT gene promoter. Genenta is also studying Temferon in additional solid tumor settings, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Beyond this program, the company is working on a biologic platform designed to deliver immunomodulatory molecules directly to tumors through infiltrating monocytes and macrophages. Genenta was incorporated in 2014.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GNTA
|
$1.79
|
14.4% Upside
|
Fair
|
$6.80
|
335.4% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
—
|
-4.9x
|
1.5x
|
—
|
37.274 M
|
13.089 M
|
18.9%
|
58.8%
|
3.5
|
—
|
105.3%
|
